AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
One of the first examples of this type of measurement has been clumped isotopes of methane.(See section of "natural gas" in Fossil fuels) Another strength of this kind of instruments is the ability to do site-specific isotopic ratio measurements. This technique is based on measuring DHRs of fragments from the ion source (e.g. CH3CH+2 of propane molecule) that samples hydrogen atoms from different parts of the molecule. In summary, direct molecular mass-spectrometry has been commonly used to measure laboratory spiked isotope tracers. Recently advanced high resolution gas source isotope ratio mass spectrometers can measure hydrogen isotopes of organic molecules directly. These mass spectrometers can provide high precision and high sensitivity. The drawback of this type of instruments includes high cost, and standardization difficulty. Also, studying site-specific isotopes with mass spectrometry is less straightforward and needs more constraints than the SNIF-NMR method, and can only distinguish isotopologues but not isotopomers.
It was thus becoming increasingly evident that the alternative of "democratic rupture" accompanied by "decisive national action" was not viable, so its main supporter, the Communist Party of Spain, decided in March 1976 to change strategy and adopt the alternative of "agreed democratic rupture" advocated by the moderate opposition and the PSOE ─ which had formed the Democratic Convergence Platform ─ although without abandoning the mobilization of citizens to exert continuous pressure on the government and force it to negotiate with the opposition. The change of strategy of the PCE, allowed the merger on March 26 of the two unitary organizations of the opposition, the Junta Democrática and the Plataforma de Convergencia Democrática, which led to the creation of Coordinación Democrática ─ popularly known as Platajunta. In its first manifesto, it rejected the "Arias-Fraga reform" and demanded an immediate political amnesty, full trade union freedom and a "rupture or democratic alternative through the opening of a constituent period". Thus, from the first scenario of rupture with popular uprising, the demand for the calling of general elections from which a constituent process could be derived. Shortly after the Platajunta was formed the government tolerated the socialist trade union Unión General de Trabajadores (UGT) to hold inside the country its XXX Congress camouflaged under the term Jornadas de Estudio (Study Days), but at the same time the police arrested the leader of CC OO, Marcelino Camacho.
A macrophage-activating factor (MAF) is a lymphokine or other receptor based signal that primes macrophages towards cytotoxicity to tumors, cytokine secretion, or clearance of pathogens. Similar molecules may cause development of an inhibitory, regulatory phenotype. A MAF can also alter the ability of macrophages to present MHC I antigen, participate in Th responses, and/or affect other immune responses. MAFs act typically in combination to produce a specific phenotype.
GTP = 3′,5′-cyclic GMP + diphosphate It is often part of the G protein signaling cascade that is activated by low intracellular calcium levels and inhibited by high intracellular calcium levels. In response to calcium levels, guanylate cyclase synthesizes cGMP from GTP. cGMP keeps cGMP-gated channels open, allowing for the entry of calcium into the cell. Like cAMP, cGMP is an important second messenger that internalizes the message carried by intercellular messengers such as peptide hormones and nitric oxide and can also function as an autocrine signal. Depending on cell type, it can drive adaptive/developmental changes requiring protein synthesis. In smooth muscle, cGMP is the signal for relaxation, and is coupled to many homeostatic mechanisms including regulation of vasodilation, vocal tone, insulin secretion, and peristalsis. Once formed, cGMP can be degraded by phosphodiesterases, which themselves are under different forms of regulation, depending on the tissue.
23 September – Media outlets, including BBC News, report that a number of firearms officers have stepped back from their role within the Metropolitan Police after a colleague was charged with murder over the shooting of Chris Kaba. Former prime minister Boris Johnson warns present prime minister Rishi Sunak against building what he describes as a "mutilated" version of HS2 following reports that the northern leg of the route from Birmingham to Manchester could be scrapped amid concerns over spiralling costs. 24 September – The Ministry of Defence is offering the Metropolitan Police armed soldiers to support its officers after several firearms officers handed in their weapons. Greater Manchester becomes the first area of England to reverse bus deregulation with the launch of its Bee Network, whereby bus services are franchised by the local authority to bus companies. 25 September – NHS England announces that more than one million appointments and treatments have been lost due to strike action by NHS staff. Mayor of Greater Manchester Andy Burnham says that scrapping the HS2 rail link between Birmingham and Manchester risks "ripping the heart" out of plans to improve rail services across northern England. 27 September – Comer Homes Group is ordered to demolish two tower blocks it built as part of the Mast Quay Phase II complex after Greenwich Borough Council planners determined the blocks differed significantly from the original plans that were submitted and approved in 2012.
Sources: en.wikipedia.org
== University of California == Upon graduating B.Sc. from Adelaide in 1905, he accepted the physiologist and cell biologist Jacques Loeb's offer of a (paid) junior position in the Physiology Department of the University of California's School of Medicine; and, according to Hedley Marston, as well as "enjoy[ing] the intellectual companionship and friendship of Jacques Loeb" at Berkeley, he also enjoyed "the pleasant and inspiring association of his colleagues": who included Winthrop J. V. Osterhout, Hardolph Wasteneys, Frederick P. Gay, Wolfgang Ostwald, Carl L. A. Schmidt, and Alonzo E. Taylor. With his developing interest in physical chemistry, and his Bragg-generated interest in mathematics, he produced two papers in 1908 (BR.5, BR.6), offering "[an] extrapolation of ... [his own] mathematical models for cell growth ... to theories to account for the normal rate of growth of individual organisms". While working with Loeb at Berkeley Robertson became interested in the physical chemistry of proteins; and, in 1912, he published a monograph on the subject (BR.9), in German. It was translated into Russian, by V. M. Arkhangeleski of the University of Moscow, in 1913; and an expanded English version of the original monograph was published five years later, in 1918 (BR.32).
==== Neurocognitive and behavioral consequences ==== Nocturnal sleep fragmentation has been linked to neurocognitive impairments, therefore, the identification of SDB such as OSA is crucial in children, those impairments having the possibility to be reversible with the appropriate treatment for the sleep disorder. The neurocognitive and behavioral dysfunctions commonly present in children with OSA include the following: hyperactivity, impulsivity, aggressive behaviors, low social and communication abilities and reduced adaptive skills. Children with OSA commonly show cognitive deficits, resulting in attention and concentration difficulties, as well as lower academic performance and IQ. Poor academic performances have been linked to OSA and suggested to result from cortical and sympathetic arousals and hypoxemia which affects memory consolidation. A study with Indian children affected by OSA has shown poor school grades, including mathematics, science, language, and physical education. This study allowed us to see the overall impact of OSA on learning abilities associated with language or numeracy skills and physical development. It has been suggested that the deficits in academic performance related to OSA could be mediated through reduced executive functions or language skills, those domains contributing highly to learning abilities and behavior. The deficits in school performance can nevertheless be improved if adenotonsillectomy is performed on children to treat the OSA.
Chloroformates are a class of organic compounds with the formula ROC(O)Cl. They are formally esters of chloroformic acid. Most are colorless, volatile liquids that degrade in moist air. Important chloroformate esters include 4-nitrophenyl chloroformate, fluorenylmethyloxycarbonylchloride, benzyl chloroformate and ethyl chloroformate. A simple example is methyl chloroformate, which is also commercially available. Chloroformates are used as reagents in organic chemistry. For example, benzyl chloroformate is used to introduce the Cbz (carboxybenzyl) protecting group and fluorenylmethyloxycarbonyl chloride is used to introduce the FMOC protecting group. Chloroformates are popular in the field of chromatography as derivatization agents. They convert polar compounds into less polar more volatile derivatives. In this way, chloroformates enable relatively simple transformation of large array of metabolites (aminoacids, amines, carboxylic acids, phenols) for analysis by gas chromatography / mass spectrometry.
National DNA Day, 25 April 2006 Moderated Chat Transcript Archive Independent On Line article about Consciousness, 7 June 2006. Siegel RM, Callaway EM (December 2004). "Francis Crick's Legacy for Neuroscience: Between the α and the Ω". PLOS Biology. 2 (12): e419. doi:10.1371/journal.pbio.0020419. PMC 535570. PMID 17593891. 100 Scientists and Thinkers: James Watson and Francis Crick from Time magazine. Francis Crick: Nobel Prize 1962, Physiology or Medicine[link removed] First press stories on DNA but for the "second" DNA story in The New York Times, see: https://www.nytimes.com/packages/pdf/science/dna-article.pdf — for reproduction of the original text in June 1953. 50th anniversary series of articles -from The New York Times. Quotes Archived 7 February 2009 at the Wayback Machine of Robert Olby on exactly who may have discovered the structure of DNA. A celebration of Francis Crick's life in science. Francis Crick tells his life story at Web of Stories Bretscher M, Lawrence P (August 2004). "Francis Crick 1916–2004". Current Biology. 14 (16): R642–5. Bibcode:2004CBio...14.R642B. doi:10.1016/j.cub.2004.08.006. PMID 15324677. Article by Mark Steyn from The Atlantic in 2004. Review of Francis Crick: Hunter of Life's Secrets in Current Biology[link removed].
In this instance reversal of paralysis will not occur until the damaged terminal axons at the neuromuscular junction have recovered, this may take days or weeks. The drug may also be used for reversal of neuromuscular blockade at the end of a surgical procedure.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.